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Abstract 
Primary abnormalities in the dystrophin gene underlie x-linked muscular dystrophy. 
However, the absence of the dystrophin isoform Dp427 does not necessarily result in a 
severe dystrophic phenotype in all muscle groups. Distal mdx muscles, namely extraocular 
and toe fibres, appear to represent a protected phenotype in muscular dystrophy. Thus, a 
comparative analysis of affected versus naturally protected muscle cells should lead to a 
greater knowledge of the molecular pathogenesis of inherited neuromuscular disorders. 
Furthermore, rationalising the protective cellular mechanisms might help in developing 
new treatment strategies for muscular dystrophy. The rescuing of extraocular and toe 
muscle fibres has previously been attributed to the special protective properties of fast-
twitching small-diameter fibres. More recent biochemical studies have shown that the up-
regulation of the autosomal dystrophin homologue named utrophin and the concomitant 
rescue of dystrophin-associated glycoproteins also plays an important role in the 
mechanical stabilisation of Dp427-deficient fibres. This result is mirrored in the dystrophic 
mdx brain where the dystrophin isoform Dp71 seems to be responsible for the preservation 
of the dystroglycan complex. It is envisaged that future proteomics-based comparisons of 
naturally protective extraocular, toe and brain tissues with severely affected skeletal muscle 
fibres will greatly add to our general understanding of the pathophysiology of muscular 
dystrophy. 
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Duchenne muscular dystrophy (DMD) represents an 
x-linked muscle disease that belongs to a large group of 
neuromuscular disorders characterised by the 
progressive degeneration of voluntary muscles. DMD is 
the most prevalent type of muscular dystrophy and 
affects an estimated 1 in 3,500 boys world-wide [28]. 
The gene responsible for DMD, localized to the Xp21 
region, encodes a very large protein named dystrophin. 
Dystrophin is required inside muscle cells for structural 
support [36] and is thought to strengthen the muscle 
periphery by anchoring elements of the membrane 
cytoskeleton to the surface membrane [13, 17, 46]. 
Dystrophin-deficient cell membranes become more 
susceptible to exercise-induced rupturing, so that 
surface signal transduction mechanisms and 
sarcolemmal ion fluxes may be disturbed [1, 19, 21]. 
The subsequent immune response can add to the 
membrane damage. 
The DMD gene is functionally one of the largest 
known, spanning ~ 2.5 Mb of genomic sequence at the 
Xp21 region. The full length 14-kb mRNA transcribed 
from the DMD locus was found to be predominately 
expressed in skeletal and cardiac muscle with smaller 
amounts in brain tissue [17, 45]. The resulting protein is 
made up of 3,685 amino acids and has a relative 
molecular mass of 427 kDa. Expression of the full-
length dystrophin transcript is controlled by three 
independently regulated promoters termed the brain (B), 
muscle (M), and purkinje (P) promotors, resulting in the 
splicing to a common set of 78 exons [9, 29, 45]. The 
names of these promoters reflect the major site of 
dystrophin expression. The B promoter drives 
expression mainly in the brain, cortical neurons and 
hippocampus regions, while the P and M promoters are 
primarily concerned with expression in the purkinje 
cells and muscle fibres, respectively. In addition to these 
three main promoters, there exist at least four internal 
promoters that give rise to shorter dystrophin 
transcripts, specifically a 240 kDa retinal isoform 
Dp240 [26], a Schwann cell-specific Dp116 [12] and 
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the brain isoforms Dp71 and Dp140 [39]. The 
dystrophin isoform Dp71 is detected in most non-
muscle tissues including brain, kidney, liver and lungs 
[31]. Alternative splicing at the 3’-end of the dystrophin 
gene generates an even greater number of isoforms [8]. 
Localization studies of muscle dystrophin have 
determined an almost exclusive localization to the 
cellular periphery on the cytoplasmic facade of the 
sarcolemma, where it comprises approximately two 
percent of the isolated plasmalemmal protein 
complement and at least five percent of the membrane 
cytoskeleton [17, 46]. The major skeletal muscle 
dystrophin isoform is a membrane cytoskeletal element 
of apparent 427 kDa and is a member of the spectrin 
protein family [37]. The dystrophin molecule can be 
structurally divided into four separate regions based on 
sequence homologies and protein-binding capabilities 
[37]. It is made up of an amino-terminal actin-binding 
domain followed by central spectrin-like repeats, a 
cysteine-rich domain, and a unique carboxy-terminal 
domain. The amino-terminus and a region in the rod 
domain of dystrophin and utrophin bind directly to 
cortical actin [57]. The full-length utrophin isoform 
Up395 represents an autosomal homologue of the 
dystrophin isoform Dp427 [11, 40]. In humans, its gene 
is located on chromosome 6. The expressed utrophin 
protein is about seven percent shorter than x-linked 
encoded dystrophin, but has a very similar structure and 
actin-binding function. It is present in many body 
tissues. In skeletal muscle fibres, it is highly enriched at 
the neuromuscular junction [47], the region where the 
motor nerve contacts the muscle surface membrane. 
Utrophin appears to be able to substitute, at least 
partially, for missing dystrophin molecules [55]. This 
was illustrated by a dystrophic mdx mouse model, 
whose utrophin gene was knocked out experimentally. 
This double-mutant lacks both dystrophin and utrophin 
and exhibits an extremely severe dystrophic phenotype 
[22, 51]. 
The dystrophin-associated protein complex is 
composed of a group of surface proteins, which are 
involved in linking the extracellular matrix to the actin 
membrane cytoskeleton [13, 16, 46]. The physical 
coupling between laminin and cortical actin via the 
dystroglycans and dystrophin is proposed to stabilise the 
sarcolemma during the rigors of repeated cycles of 
contraction and relaxation [46]. In addition, the 
dystrophin-glycoprotein complex transmits the force 
generated in the muscle sarcomeres to the extracellular 
matrix. See Figure 1 for a diagrammatic presentation of 
the dystrophin-associated surface complex from skeletal 
muscle, including dystrophin, dystroglycans, 
sarcoglycans, dystrobrevin, sarcospan, and laminin. 
Also shown is what specific forms of muscular 
dystrophy can be attributed to changes in the expression 
levels of particular surface proteins. Depending on the 
specific type of mutation, genetic abnormalities in the 
dystrophin gene lead to either severe Duchenne 
muscular dystrophy or more benign Becker muscular 
dystrophy [43]. Mutations in the members of the 
sarcoglycan sub-complex result in the various types of 
limb girdle muscular dystrophy [13, 27]. Muscle 
laminin is an amalgamation of various peptide chains 
[49]. Mutations in the gene expressing this protein cause 
severe congenital muscular dystrophy [13]. 
Utrophin and the rescue of mdx extraocular and 
toe muscle fibres 
The fact that small calibre muscle fibres are not 
severely affected in muscular dystrophy has long been 
established [35]. Recently, it has been suggested that the 
protective factor involved in this process is the 
dystrophin-related protein named utrophin. Full-length 
utrophin is highly enriched at neuromuscular junctions 
and co-localises with the nicotinic acetylcholine 
receptor complex in normal skeletal muscle fibres [47]. 
The predicted primary structure is similar to that of 
dystrophin [40, 50]. It has been suggested that levels of 
utrophin in muscle fibres of patients with DMD could 
be raised to functionally compensate for the absence of 
 
Figure 1. Diagrammatic presentation of the 
composition of the dystrophin-associated protein 
complex and its involvement in muscular 
dystrophies. A trans-sarcolemmal linkage is 
provided by the interactions between the actin-
binding protein dystrophin via the α/β-
dystroglycan complex and the extracellular 
matrix protein laminin. Other dystrophin-
associated elements are represented by 
dystrobrevins, syntrophins, sarcoglycans and 
sarcospan. Primary genetic abnormalities in 
members of the dystrophin-glycoprotein complex 
lead to various forms of muscular disorders: (i) 
dystrophin – Duchenne muscular dystrophy 
(DMD), Becker muscular dystrophy (BMD), X-
linked dilated cardiomyopathy (XLMD, (ii) 
sarcoglycans: limb-girdle muscular dystrophy, 
and (iii) laminin – congenital muscular 
dystrophy (CMD). Another form of limb-girdle 
muscular dystrophy is triggered by mutations in 
caveolin. 
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dystrophin because of the similarities between the two 
proteins, therefore implicating utrophin as having an 
important therapeutic value [55]. Comparative 
immunoblot analysis of gastrocnemius and toe muscle 
specimens from the naturally occurring mdx mouse, an 
established model system of DMD pathology [2] 
revealed that the distal mdx muscle group exhibited an 
up-regulation of utrophin and a rescuing of the 
dystrophin-associated protein complex [24]. In 
dystrophic leg muscles, the absence of dystrophin 
causes the loss of several sarcolemmal glycoproteins, 
disrupting the link between the extracellular matrix and 
the membrane cytoskeleton, thereby rendering the fibres 
more susceptible to necrosis, stretch induced injury, 
osmotic shock and exhibit calcium induced net 
degradation of muscle proteins [1, 6, 17, 19, 46]. 
Although lacking the dystrophin isoform Dp427, the 
expression levels of sarcoglycans and dystroglycans are 
relatively comparable in mdx toe fibres to that of 
normal muscle fibres. It has been previously shown that 
utrophin localises extra-junctionally in extraocular and 
toe fibres from the mdx mouse model [42]. Therefore, 
utrophin might act as a molecular substitute anchoring 
the dystrophin-associated protein complex in Dp427-
deficient tissue. Hence, utrophin establishes a link 
between the actin membrane cytoskeleton and the 
extracellular matrix, helping to prevent down-stream 
calcium induced protein degradation. 
The mdx mouse exhibits a moderate form of muscular 
dystrophy and a life span greater than one year, whereas 
the utrophin null mouse shows no muscular dystrophy 
and has a life span similar to that of wild-type mice. In 
stark contrast, the dystrophin-utrophin null mouse (Utrn-
/-/mdx) exhibits a severe muscular dystrophy and a short 
life span, between four and twenty weeks [22], 
suggesting an important role for utrophin in 
sarcolemmal membrane integrity. A comparative 
histochemical analysis between normal gastrocnemius, 
mdx gastrocnemius and mdx toe muscle fibres clearly 
showed a difference in peripherally located nuclei. The 
observation that mdx toe fibres show mostly peripheral 
located nuclei indicate strongly that, although lacking 
Dp427, the fibres do not exhibit the same degree of 
degeneration as seen in mdx gastrocnemius muscle 
fibres. This supports the hypothesis that utrophin infers 
some degree of stability to the dystrophin-associated 
protein complex [24]. Certainly other cellular factors 
besides the up-regulation of utrophin are involved in the 
sparing of the distal mdx muscle fibres. These are a 
lower mechanical stress per unit surface membrane area 
and perhaps different metabolic processes. The fact that 
utrophin is structurally and functionally similar to that 
of dystrophin opens up an important avenue with 
respect to gene therapy and pharmacological 
intervention. Utrophin gene therapy has added 
advantages over some of the other areas of possible 
therapy. Since utrophin is naturally produced in low 
levels by boys suffering from DMD or BMD, their 
bodies would not recognise utrophin as foreign. This 
means that if the utrophin gene was inserted as a means 
of gene therapy to increase utrophin levels the problem 
of immunological rejection may be overcome. Usually 
when a foreign substance is seen by the body's immune 
system, it will recognise it as foreign and will trigger an 
appropriate immune response. However, since utrophin 
is not considered foreign to the body, the immune 
defence system does not react to it unlike dystrophin. 
Since utrophin is naturally found in various cell types, 
an increased amount of utrophin in non-muscle tissues 
does not appear to have any detrimental side effects in 
the mdx mouse. Consequently a gene therapeutic 
approach does not necessarily have to target utrophin 
specifically to skeletal muscle cells. 
Preserved β-dystroglycan expression in 
extraocular and toe mdx muscle fibres 
The first component of the dystrophin-associated 
glycoprotein complex to be cloned was dystroglycan, 
which produces a precursor protein that is processed to 
generate α- and β-dystroglycan [32]. In skeletal muscle, 
β-dystroglycan was found to exhibit an apparent 
molecular mass of 43 kDa. It consists of a single 
transmembrane domain and is inserted into the muscle 
plasma membrane with the carboxy-terminus on the 
cytoplasmic side. The last 15 amino acids of β-
dystroglycan, rich in proline residues and containing 
sites for tyrosine phosphorylation, appear to bind 
directly to the cysteine-rich region of dystrophin [33, 
34, 52], thus establishing the link between the actin 
cytoskeleton and the sarcolemma. An established 
feature of dystrophin-deficient skeletal muscle fibres is 
the drastic reduction in various surface glycoproteins 
[48]. As illustrated in Figure 2, immunoblotting 
confirmed the previously shown dramatic reduction of 
β-dystroglycan in Dp427-deficient mdx gastrocnemius 
membrane preparations [13, 46]. In contrast, in mdx 
extraocular and toe fibres the expression level of this 
key member of the membrane-spanning complex was 
comparable to that in normal gastrocnemius (Figure 
2C). Control blots show that the relative density of the 
α2-subunit of the dihydropyridine receptor and laminin 
is not altered in the three tissues studied (Figure 2A, D). 
Comparative immuno fluorescence microscopy 
confirmed the sarcolemmal localization of β-dystroglycan 
in normal gastrocnemius muscle and showed a drastically 
reduced expression in Dp427-deficient mdx fibres [25]. 
Figure 3A shows the relatively weak surface labelling of 
β-dystroglycan in mdx gastrocnemius and the 
predominant central nucleation in dystrophic cells. In 
contrast to dystrophic gastrocnemius, the degree of 
central nucleation is considerably less in extraocular mdx 
fibres (Figure 3B). The active regeneration of muscle to 
repair or replace lost or damaged fibres is signified by 
centralized nuclei, small fibre size and basophilic RNA-
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rich cytoplasm [6, 10]. Fibres undergoing necrosis and 
regeneration seem to do so in groups for a reason not 
fully comprehended, possibly due to incomplete lateral 
fusion of the myofibres or mast cell mediated 
myocytotoxicity [30]. The intense labelling of β-
dystroglycan in the extraocular mdx fibre periphery 
demonstrates the sarcolemmal rescue of this dystrophin-
associated glycoprotein (Figure 3B) suggesting that 
extraocular mdx muscles represent a naturally protected 
phenotype. 
Up-regulation of Ca2+-ATPase in extraocular mdx 
muscle fibres 
Abnormal Ca2+-handling has been postulated to play a 
major role in the end-stage pathology of muscular 
dystrophy [1, 21]. The calcium hypothesis of muscular 
 
Figure 2. Comparative immunoblot analysis of 
microsomes isolated from normal and dystrophic 
mdx gastrocnemius, extraocular and toe muscle 
fibres. Shown are immunoblots labelled with 
monoclonal antibodies to the α2-subunit of the 
dihydropyridine receptor of the transverse 
tubules (α2-DHPR) (A), the full-length Dp427 
isoform of the membrane cytoskeletal protein 
dystrophin (B), the 43 kDa sarcolemmal 
glycoprotein β-dystroglycan (β-DG) (C), and the 
extracellular matrix protein laminin (LAM) (D). 
Lanes 1 to 6 contain membranes from normal 
(nor) and dystrophic (mdx) gastrocnemius 
(Gastroc.), extraocular (Extraoc.) and toe 
muscle fibres, respectively. Membranes were 
prepared and analysed by standard methodology 
[21]. Although deficient in dystrophin, both 
extraocular and toe mdx microsomes contain β-
dystroglycan levels comparable to normal 
muscle fibres. This strongly indicates that these 
mdx fibres represent a naturally protected 
phenotype. 
 
Figure 3. Comparative immunofluorescence analysis of 
dystrophic gastrocnemius and extraocular 
fibres.  Shown is the immuno-decoration of mdx 
gastrocnemius (A) and mdx extraocular muscle 
fibres (B) using 10 µm cyrosections stained with 
primary antibodies to β-dystroglycan (β-DG) 
and secondary fluorescein-conjugated 
antibodies [25]. Incubation with the DNA-
binding dye diamidino-phenyindole (DAPI) was 
used to label nuclei. The direct comparison of 
the fluorescein labelling intensity of β-
dystroglycan demonstrated a higher expression 
levels of β-dystroglycan in mdx extraocular 
fibres as compared to mdx gastrocnemius 
muscle. DAPI staining revealed a high degree of 
central nucleation in mdx gastrocnemius 
sections and more peripheral nucleation in mdx 
extraocular fibres indicating that 
degeneration/regeneration-cycles are not as 
active in the extraocular fibres as compared to 
gastrocnemius cells. 
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dystrophy [19] assumes that the deficit of the linkage 
between the extracellular matrix component laminin and 
the actin membrane cytoskeleton, normally provided by 
the dystrophin-associated protein complex, impairs the 
structural integrity of the muscle plasmalemma [15]. As a 
result, dystrophin-deficient skeletal muscle membranes 
yield to exercise-induced membrane ruptures more 
frequently than those of normal fibres. Smaller diameter 
fibres, such as extraocular and toe muscle fibres, do not 
appear to be as severely affected as bulk muscle fibres 
such as gastrocnemius tissue [21, 35]. Transient micro-
rupturing allows for the introduction of proteolytically 
activated Ca2+-leak channels into the sarcolemma [1] 
during the natural processes of cell membrane resealing 
[7]. This triggers a localized sub-sarcolemmal accu-
mulation of Ca2+-ions [56]. A pathophysiological 
consequence of abnormal Ca2+-handling [1] and 
membrane defects [44] is impaired excitation-contraction 
coupling [23]. The raised cytosolic Ca2+-levels allow for 
activation of Ca2+-dependent proteases, causing further 
channel activation and general protein degradation. An 
example being the calpains, which are muscle specific 
and potent proteolysis instigators [1, 5, 54]. In addition, 
the reduced expression of several luminal calsequestrin-
like proteins (CLPs) and a general decrease in the ability 
of the sarcoplasmic reticulum (SR) to properly sequester 
Ca2+-ions allows for abnormal Ca2+- buffering [21]. This 
might be a contributing aspect to the raised cytosolic 
Ca2+-levels. In contrast, mitochondria in close proximity 
to ryanodine receptor Ca2+-release channel complexes at 
the membrane face of the sarcoplasmic reticulum buffer a 
certain degree of elevated Ca2+-levels. Irregularities in 
mitochondrial function, however, are postulated to lead to 
the generation of pro-apoptotic factors, resulting 
eventually in muscle degeneration [38, 41, 53]. 
Ca2+ re-uptake is a vital step during muscle relaxation, 
it was therefore of interest to study the fate of the major 
sarcoplasmic reticulum Ca2+-ATPase isoform SERCA1 
in muscular dystrophy [25]. The Ca2+-ATPase activity 
was shown to be drastically increased in extraocular mdx 
fibres. Comparative immunoblotting also uncovered an 
increase in the expression level of the SERCA1 ion pump 
species, indicating a potential adaptive response in these 
dystrophin-deficient fibres. The increased removal of 
cytosolic Ca2+-ions from small-diameter fibres, via the 
up-regulation of this predominant Ca2+-pump, might 
protect dystrophin-deficient muscle cells from Ca2+-
induced myonecrosis [25]. Since calsequestrin-like 
protein levels are reduced in mdx gastrocnemius muscle, 
a decreased capacity for Ca2+-ion buffering and storage 
exists in the dystrophic sarcoplasmic reticulum, with a 
consequence of increased cytosolic proteolysis via Ca2+-
mediated enzymes. Therefore, the increased removal of 
excess Ca2+-ions by up-regulated SERCA1 units might 
counter-act these pathophysiological changes. A more 
detailed study of the differences between an affected 
muscle group and a protected phenotype might pave the 
way for vital therapeutic and pharmacological 
intervention, as is demonstrated by the deployment of 
protease inhibitors such as carnitine-linked leupeptin in 
order to inactivate Ca2+-dependent calpain activity [5]. 
Histologic analysis of treated muscles, in comparison to 
untreated mdx myofibers, consistently showed increases 
of myofiber diameter. In addition, there was a clear 
correlation between increased myofiber size and 
decreased calpain activities in leupeptin treated muscles 
[5]. Pharmacological intervention directed towards key 
calcium handling proteins, abnormally expressed in 
dystrophic tissue, such as the SERCA1 pump and the 
CLPs might offer a worthy target in the treatment of the 
muscular dystrophies. 
Persistent Dp71 expression in mdx brain tissue 
The major dystrophin protein product in brain, Dp71, is 
expressed in astrocytes and glial cells [4, 14]. It contains 
the carboxy-terminal and the cysteine-rich domains of 
dystrophin, and seven additional amino acids at the 
amino-terminus. It lacks the entire large central domain 
of spectrin-like repeats and the actin-binding domain of 
dystrophin [4]. The Dp71 isoform represents the major 
DMD gene product in brain and other non-muscle tissues. 
The trans-membrane link is maintained by an interaction 
between Dp71 and β-dystroglycan, which in turn 
interacts with α-dystroglycan, thus establishing the 
membrane spanning dystroglycan sub-complex [20]. Our 
analysis of normal and mdx brains showed the expression 
levels of Dp71 to be similar in the two tissues, with the 
abundance levels of both α- and β-dystroglycan 
exhibiting no major difference (Figure 4D, E). While the 
protein complement of normal and mdx brain 
microsomes was found to be very similar, the dystrophin 
isoform Dp427 is completely absent in mdx brain (Figure 
4A, B). Although Dp71 co-localizes with β-dystroglycan, 
the lack of full-length brain dystrophin seems to trigger a 
disturbed organization of the dystroglycan sub-complex 
[18]. In dystrophic forebrain, β-dystroglycan expression 
is not drastically affected, possibly due to the up-
regulation of utrophin isoforms which partially 
compensate for the deficiency in brain dystrophins. 
Together with Dp71, which exists in contrast to its 
normally oligomeric form in mdx brain as a monomeric 
protein, brain utrophins confer a degree of stability on the 
dystrophin-associated protein complex in Dp427-
deficient brain [18]. In analogy to the naturally protected 
extraocular and toe mdx fibres, comparative 
investigations into the adaptive changes in the dystrophic 
mdx brain might lead to the discovery of new therapeutic 
targets in the treatment of muscular dystrophy. 
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Proteomics analysis of Muscular Dystrophy 
Potential problems associated with myoblast and gene 
therapy, namely immune rejection and cytotoxic side 
effects, have led to novel approaches in tackling muscular 
dystrophy [3, 55]. One of them is the usage of high-
resolution two-dimensional gel electrophoresis in 
conjunction with mass spectroscopy in order to identify 
novel proteins involved in this disorder. Proteomics-
based research strategies directed towards the 
determination of abnormally expressed proteins in control 
versus dystrophic leg muscle, as compared to that of 
protected phenotypes (exemplified by mdx extraocular, 
toe and brain tissues) represent a new scientific angle in 
the treatment for muscular dystrophy. The general 
protocol of such an approach is outlined in the flow chart 
of Figure 5. For example, high-throughput analyses based 
on mass spectroscopy might detect rescuing pathways by 
which utrophin abolishes the dystrophic phenotype. 
Utrophin up-regulation, whether it occurs through gene 
transfer or pharmacological intervention, is an exciting 
option. The increased expression of the Up395 protein in 
 
Figure 4. Comparative immunoblot analysis of normal 
and dystrophic mdx brain microsomes. Shown is 
a Coomassie-stained gel (A) of normal (lane 1) 
and dystrophic (lane 2) brain membranes, as 
well as identical immunoblots lebelled with 
antibodies to the two brain dystrophin isoforms 
of 427 kDa (Dp427) and 71 kDa (Dp71) (B), 
laminin (LAM) (C), α-dystroglycan (α-DG) (D), 
and β-dystroglycan (β-DG). The major 
dystrophin isoform in brain, Dp71, appear to be 
unaffected in the Dp-427-deficient brain tissue 
and might thus compensate for the lack of full-
length dystrophin in stabilising the dystrophin-
associated complex. Brain membranes were 
prepared and analysed by standard methodology 
[18]. Molecular mass standards (in kDa) are 
indicated at the left. 
 
Figure 5. Flow chart of a proteomics-based research 
strategy to identify novel therapeutic targets in 
dystrophic muscle. Total skeletal muscle 
extracts from normal tissues and mdx 
gastrocnemius, mdx extraocular, and mdx 
brain will be subject to one-dimensional 
separation using isoelectric focusing. 
Subsequently high-resolution sodium dodecyl 
sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) will be performed in the second 
dimension in order to establish a total protein 
expression profile. Abnormally expressed 
proteins can then be determined by density 
scanning and identified by peptide sequencing, 
mass spectroscopy and/or immunoblotting. This 
high-throughput  approach might be useful in 
the initial characterization of novel candidate 
proteins implicated in the protection of the 
dystrophin-associated protein complex.  
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mdx toe fibres appears to functionally compensate for the 
absence of dystrophin in Dp427-deficient tissue. 
Substituting utrophin seems to establishing a proper 
linkage between the extracellular matrix and actin 
membrane cytoskeleton in certain dystrophic fibres. 
Dystrophin-related proteins, along with the various 
Ca2+-handling proteins, merit consideration in 
identifying novel therapeutic targets in dystrophic 
muscle. Through the processes of protein isolation, 
electrophoretic separation, peptide digestion and 
sequencing, mass spectroscopy and verification by 
immunoblotting, new candidate proteins may be 
identified. 
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